...
首页> 外文期刊>Neurocomputing >Neural network models for supporting drug and multidrug resistant tuberculosis screening diagnosis
【24h】

Neural network models for supporting drug and multidrug resistant tuberculosis screening diagnosis

机译:支持药物和耐多药结核病筛查诊断的神经网络模型

获取原文
获取原文并翻译 | 示例
           

摘要

Tuberculosis (TB) is the leading cause of global mortality among communicable diseases. The diagnosis of Drug-Resistant Tuberculosis (DR-TB) demands even more attention, leading to longer treatments and higher deceased rates. All diagnostic methods available have deficiencies in their detection rates, time release results, or have a higher cost and need a complex infrastructure to setup. New molecular diagnostics, such as the Xpert MTB/RIF assay, have great potential for revolutionizing the diagnosis of Rifampicin Resistance (RR). But, a positive RR result with this test should be carefully interpreted and take into consideration the risk of Multidrug-Resistant TB (MDR-TB) according to its prevalence, locally. Therefore, the development of screening approaches for DR/MDR-TB suspects would help to identify those should be tested by Xpert MTB/RIF. This work develops Artificial Neural Network (ANN) models considering data from presumed DR/MDR-TB subjects, according to the National Guidelines at Rio de Janeiro/Brazil, attended in reference centers in Rio de Janeiro, from Feb 2011 and May 2013. Subjects aged 18 years or older, and results were compared with models based on Classification And Regression Trees (CART). Practical operation at different epidemiological scenarios are considered by constructing models using different variable selection criteria, so that environments with low resource conditions can be assisted. Among 280 presumed DR-TB cases included, 38 were DR-TB, 48-MDR, 32-Drug-Sensitive and 162 with no TB. Between DR-TB and non DR-TB, the sensitivity and specificity reached 95.1%(5.0) and 85.0%(4.9), respectively. The promising results of clinical score for DR/MDR-TB diagnosis indicate that this approach may be used in the evaluation of presumed DR/MDR-TB. (C) 2017 Elsevier B.V. All rights reserved.
机译:结核病(TB)是传染病中全球死亡率的主要原因。耐药结核病(DR-TB)的诊断需要更多的关注,从而导致更长的治疗时间和更高的死亡率。所有可用的诊断方法在检测率,时间释放结果上均存在缺陷,或者具有较高的成本,并且需要复杂的基础架构来设置。 Xpert MTB / RIF分析等新的分子诊断方法具有巨大的潜力,可彻底改变对利福平耐药性(RR)的诊断。但是,应仔细解释该试验的阳性RR结果,并应根据其局部患病率考虑耐多药结核病(MDR-TB)的风险。因此,开发针对DR / MDR-TB嫌疑人的筛查方法将有助于识别应由Xpert MTB / RIF进行检测的方法。根据2011年2月至2013年5月在里约热内卢参考中心参加的巴西里约热内卢/巴西国家指南,这项工作考虑了来自假定的DR / MDR-TB受试者的数据,开发了人工神经网络(ANN)模型。年龄在18岁或以上,并将结果与​​基于分类和回归树(CART)的模型进行比较。通过使用不同的变量选择标准构建模型来考虑在不同流行病学情景下的实际操作,从而可以为资源条件低的环境提供帮助。在280例假定的DR-TB病例中,有38例是DR-TB,48例MDR,32例药物敏感和162例无结核。在DR-TB和非DR-TB之间,敏感性和特异性分别达到95.1%(5.0)和85.0%(4.9)。用于DR / MDR-TB诊断的临床评分的有希望的结果表明,该方法可用于评估假定的DR / MDR-TB。 (C)2017 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号